We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer.
- Authors
Furuse, Kiyoyuki; Kubota, Kaoru; Kawahara, Masaaki; Takada, Minoru; Kimura, Ikuro; Fujii, Masafumi; Ohta, Mitsuo; Hasegawa, Kouichi; Yoshida, Kiyokazu; Nakajima, Shigenori; Ogura, Takeshi; Niitani, Hisanohu
- Abstract
Twenty-four previously treated patients with refractory or relapsed small cell lung cancer (SCLC) were entered into a prospective, multicenter phase II study. All 24 patients had been pretreated with some form of cisplatin-based chemotherapy. The median time of chemotherapy was 4.2 months (range 1.4-9.4 months). Patients were treated with a dose of 25 mg/m2 of vinorelbine weekly. Twenty-four patients were eligible for response and for toxicity. Partial response was observed in 3 out of 24 eligible patients (12.5%; 95% confidence interval, 2.7-32.4%). All 3 patients who responded had previous chemotherapy including vincristine. The most common toxicity was leukopenia (91.7%, 66.7% in WHO 3-4 grade) and anemia (70.8%, 20.8% in WHO 3 grade). Nonhematological toxicities were moderate and mild. These results support a two-stage sequential study design of previously untreated patients for further phase II study in SCLC. Copyright © 1996 S. Karger AG, Basel
- Publication
Oncology, 1996, Vol 53, Issue 2, p169
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000227555